WuXi AppTec Issues Positive Profit Alert for the First Half of 2025
WuXi AppTec (WUXAY), a global pharmaceutical and life sciences technology platform company, has released a positive profit alert for H1 2025. The company expects total revenue of RMB20.80 billion, up 20.6% year-over-year, with revenue from Continuing Operations growing 24.2%.
Key financial highlights include an expected adjusted non-IFRS net profit of RMB6.31 billion (up 44.4% YoY), net profit after non-recurring items of RMB5.58 billion (up 26.5% YoY), and net profit attributable to owners of RMB8.56 billion (up 101.9% YoY). Basic earnings per share is projected at RMB3.01, representing a 106.2% increase.
WuXi AppTec (WUXAY), una piattaforma tecnologica globale nel settore farmaceutico e delle scienze della vita, ha pubblicato un avviso positivo sugli utili per il primo semestre 2025. L'azienda prevede un fatturato totale di 20,80 miliardi di RMB, in crescita del 20,6% rispetto all'anno precedente, con un aumento del 24,2% dei ricavi dalle operazioni continuative.
I principali dati finanziari includono un utile netto rettificato non IFRS di 6,31 miliardi di RMB (in crescita del 44,4% su base annua), un utile netto dopo voci non ricorrenti di 5,58 miliardi di RMB (in aumento del 26,5% su base annua) e un utile netto attribuibile ai proprietari di 8,56 miliardi di RMB (con un incremento del 101,9% su base annua). L'utile base per azione 猫 stimato a 3,01 RMB, con un aumento del 106,2%.
WuXi AppTec (WUXAY), una plataforma tecnol贸gica global en el sector farmac茅utico y de ciencias de la vida, ha publicado una alerta positiva de beneficios para el primer semestre de 2025. La compa帽铆a espera un ingreso total de 20.80 mil millones de RMB, un aumento del 20,6% interanual, con ingresos de operaciones continuas creciendo un 24,2%.
Los principales aspectos financieros incluyen un beneficio neto ajustado no IFRS de 6.31 mil millones de RMB (un aumento del 44,4% interanual), beneficio neto despu茅s de partidas no recurrentes de 5.58 mil millones de RMB (un aumento del 26,5% interanual) y beneficio neto atribuible a los propietarios de 8.56 mil millones de RMB (un aumento del 101,9% interanual). Las ganancias b谩sicas por acci贸n se proyectan en 3.01 RMB, representando un incremento del 106,2%.
WuXi AppTec (WUXAY)電� 旮�搿滊矊 鞝滌暯 氚� 靸濍獏瓿柬暀 旮办垹 頂岆灚韽� 旮办梾鞙茧, 2025雲� 靸侂皹旮� 旮嶌爼鞝侅澑 靾橃澋 鞝勲鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 齑� 毵れ稖鞎� 208鞏� 鞙勳晥鞚� 鞓堨儊頃橂┌, 鞚措姅 鞝勲厔 霃欔赴 雽�牍� 20.6% 歃濌皜頃� 靾橃箻鞚搓碃, 歆�靻� 鞓侅梾 攵�氍� 毵れ稖鞚� 24.2% 靹膘灔頃� 瓴冹溂搿� 鞝勲霅╇媹雼�.
欤检殧 鞛 頃橃澊霛检澊韸鸽電� 臁办爼 牍処FRS 靾滌澊鞚� 63.1鞏� 鞙勳晥(鞝勲厔 雽�牍� 44.4% 歃濌皜), 牍勲皹氤� 頃 鞝滌櫢 靾滌澊鞚� 55.8鞏� 鞙勳晥(鞝勲厔 雽�牍� 26.5% 歃濌皜), 攴鸽Μ瓿� 靻岇湢欤� 攴�靻� 靾滌澊鞚� 85.6鞏� 鞙勳晥(鞝勲厔 雽�牍� 101.9% 歃濌皜)鞚� 韽暔霅╇媹雼�. 旮半掣 欤茧嫻靾滌澊鞚奠潃 3.01 鞙勳晥鞙茧, 106.2% 歃濌皜頃� 瓴冹溂搿� 鞓堨儊霅╇媹雼�.
WuXi AppTec (WUXAY), une plateforme technologique mondiale dans les secteurs pharmaceutique et des sciences de la vie, a publi茅 une alerte positive sur ses b茅n茅fices pour le premier semestre 2025. La soci茅t茅 pr茅voit un chiffre d'affaires total de 20,80 milliards de RMB, en hausse de 20,6 % en glissement annuel, avec une croissance de 24,2 % des revenus issus des op茅rations poursuivies.
Les principaux points financiers comprennent un r茅sultat net ajust茅 non-IFRS de 6,31 milliards de RMB (en hausse de 44,4 % sur un an), un r茅sultat net apr猫s 茅l茅ments non r茅currents de 5,58 milliards de RMB (en hausse de 26,5 % sur un an) et un r茅sultat net attribuable aux propri茅taires de 8,56 milliards de RMB (en hausse de 101,9 % sur un an). Le b茅n茅fice de base par action est estim茅 脿 3,01 RMB, soit une augmentation de 106,2 %.
WuXi AppTec (WUXAY), ein globales Technologieunternehmen im Bereich Pharma und Biowissenschaften, hat eine positive Gewinnprognose f眉r das erste Halbjahr 2025 ver枚ffentlicht. Das Unternehmen erwartet einen Gesamtumsatz von 20,80 Milliarden RMB, was einem Anstieg von 20,6 % gegen眉ber dem Vorjahr entspricht, wobei der Umsatz aus fortgef眉hrten Gesch盲ftsbereichen um 24,2 % w盲chst.
Zu den wichtigsten finanziellen Kennzahlen geh枚ren ein erwarteter bereinigter Non-IFRS Nettogewinn von 6,31 Milliarden RMB (plus 44,4 % im Jahresvergleich), ein Nettogewinn nach nicht wiederkehrenden Posten von 5,58 Milliarden RMB (plus 26,5 % im Jahresvergleich) sowie ein dem Eigent眉mer zurechenbarer Nettogewinn von 8,56 Milliarden RMB (plus 101,9 % im Jahresvergleich). Das Ergebnis je Aktie wird auf 3,01 RMB gesch盲tzt, was einer Steigerung von 106,2 % entspricht.
- Total revenue growth of 20.6% YoY to RMB20.80 billion
- Adjusted non-IFRS net profit surge of 44.4% YoY to RMB6.31 billion
- Impressive 101.9% YoY increase in net profit attributable to owners
- Strong 106.2% YoY growth in basic earnings per share to RMB3.01
- Continuing Operations showing robust 24.2% YoY revenue growth
- Growth rate impacted by exchange rate fluctuations
Important notice of the announcement are as follows:
WuXi AppTec maintains a laser focus on the Company's unique, integrated and end-to-end CRDMO (Contract Research, Development and Manufacturing Organization) business model. In response to customers' ongoing demand for enabling services, the Company continues to enhance its capabilities and capacity, optimize production processes and improve operating efficiency. These factors are driving sustained long-term business growth, delivering highly efficient and exceptional services to customers and helping to bring groundbreaking therapies to patients worldwide.
- Total revenue for the first half of 2025 is expected to be approximately
RMB20.80 billion , representing a year-over-year increase of approximately20.6% , with revenue from Continuing Operations growing by approximately24.2% year-over-year. - Adjusted non-IFRS net profit for the first half of 2025 is expected to be approximately
RMB6.31 billion , representing a year-over-year increase of approximately44.4% . - Net profit after deducting non-recurring items[1] for the first half of 2025 is expected to be approximately
RMB5.58 billion , representing a year-over-year increase of approximately26.5% . The growth rate compared to the adjusted non-IFRS net profit is mainly affected by exchange rate fluctuations. - Net profit attributable to the owners of the Company[1] for the first half of 2025 is expected to be approximately
RMB8.56 billion , representing a year-over-year increase of approximately101.9% , which includes the gain on partial disposal of associates. Basic earnings per share for the first half of 2025 is expected to be approximatelyRMB3.01 , representing a year-over-year increase of approximately106.2% .
WuXi AppTec will provide additional details when the Company releases its results for the first half of 2025 on July 29, 2025.
For more information, please refer to the Company's related announcements: .
[1] Net profit after deducting non-recurring items and net profit attributable to the owners of the Company are both prepared in accordance with China Accounting Standards for Business Enterprises (CAS).
About WuXi AppTec
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across
View original content:
SOURCE WuXi AppTec
FAQ
What are WuXi AppTec's (WUXAY) expected earnings for H1 2025?
What is WuXi AppTec's projected revenue for the first half of 2025?
How much will WuXi AppTec's earnings per share grow in H1 2025?
When will WuXi AppTec release its full H1 2025 financial results?
What factors are driving WuXi AppTec's growth in 2025?
